

# Nordic–Baltic Conference in Pharmacovigilance 2026

## 2 June, Stockholm



## Program

**Conference moderators:** *Sara Maxe*, Maxe Pharma Consulting and *Patricia Jimenez Vasquez*, MSD

09.00 Registration

09.30 **Welcome and practical information**  
*Läkemedelsakademin and moderators*

09.45 **Keynote lecture:**  
**Real Life impact of drug safety work**  
*Felix Arellano*, Roche

### **Session: AI in Pharmacovigilance from authority and industry perspective**

10.15 **AI Tools for PV at the Swedish Medical Products Agency**  
*Luise Dürlich*, Swedish Medical Products Agency

10.35 **Applications of AI in PV: from Transactional tasks in Case handling and Periodic reporting to Multimodal Predictive Clinical Safety models during Drug Development**  
*Magnus Nord*, AstraZeneca

10.55 Coffee break

11.25 **Trusted use of AI in Pharmacovigilance**  
*Vijay Kara*, GSK

11.45 **Discussion**  
*Luise Dürlich*, Swedish Medical Products Agency; *Magnus Nord*, AstraZeneca; *Vijay Kara*, GSK; *Julia Appelskog*, CSL

12.05– Lunch break  
13.15

### **Session: The PV role in small vs big company – global environment vs affiliate – how to bridge similarities and benefit from the differences**

13.15 **From PV Macroformat to Microformat: Leveraging Differences, Building on Similarities**  
*Karin Kempe*, Karo Healthcare

13.35 **Global Vision Meets Local Reality: Pharmacovigilance in Small Companies, Big Pharma, and Affiliates**  
*Julia Appelskog*, CSL

13.55 **Discussion**  
*All session speakers*

### **Session: To transform EMA decisions into local practices**

14.15 **Risk minimisation materials – from PRAC – discussion to national implementation – a regulatory perspective**  
*Ulla Wändel Liminga*, MPA Sweden and PRAC

14.35 Coffee break

15.05 **Effectiveness of risk minimisation measures to prevent pregnancy exposure: an example of mycophenolate use in women of childbearing age in Estonia**  
*Katrin Kurvits*, State Agency of Medicines, Estonia

15.20 **The national agency's experience in approving digital communication tools in addition to the regular channels used for dissemination of educational materials – additional risk minimisation measures**  
*Lina Masionienė*, State Medicines Control Agency of Lithuania

15.35 **Discussion**  
*All session speakers*

### **Session: News from Regulators & a Future outlook**

15.55 **Local novelty in pharmacovigilance**  
*Liene Luce*, State Agency of Medicines, Latvia

16.10 **Farmasto – a single access point to reliable high-quality medicines information**  
*Johanna Seppänen*, Finnish Medicines Agency

16.25 **Discussion Future of PV**  
*Felix Arellano*, Roche; *Ulla Wändel Liminga*, MPA Sweden and PRAC; *Julia Appelskog*, CSL; *Johanna Seppänen*, Fimea; *Liene Luce*, State Agency of Medicines, Latvia

16.50– Closing  
17.00 *Moderators*